Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial

被引:54
作者
Mai, Elias K. [1 ]
Benner, Axel [2 ]
Bertsch, Uta [1 ,3 ]
Brossart, Peter [4 ]
Haenel, Annette [5 ]
Kunzmann, Volker [6 ]
Naumann, Ralph [7 ,14 ]
Neben, Kai [8 ]
Egerer, Gerlinde [1 ]
Ho, Anthony D. [1 ]
Hillengass, Jens [1 ]
Raab, Marc S. [1 ]
Neubauer, Andreas [9 ]
Peyn, Astrid [10 ]
Ko, Yon-Dschun [11 ]
Peter, Norma [12 ]
Scheid, Christof [13 ]
Goldschmidt, Hartmut [1 ,3 ]
机构
[1] Univ Clin Heidelberg, Dept Internal Med 5, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, Div Biostat, Heidelberg, Germany
[3] Natl Ctr Tumorerkrankungen NCT Heidelberg, Heidelberg, Germany
[4] Univ Hosp Bonn, Med Clin & Polyclin 3, Bonn, Germany
[5] Klinikum Chemnitz, Dept Internal Med 3, Chemnitz, Germany
[6] Univ Clin Wurzburg, Dept Internal Med 2, Wurzburg, Germany
[7] Univ Hosp Dresden Carl Gustav Carus, Dept Med 1, Dresden, Germany
[8] Klinikum Baden Baden, Dept Haematol & Oncol, Baden Baden, Germany
[9] Univ Clin Giessen Marburg, Dept Haematol & Oncol, Marburg, Germany
[10] Klinikum Bremen Mitte, Dept Internal Med 1, Bremen, Germany
[11] Kliniken Bonn, Dept Haematol & Oncol, Bonn, Germany
[12] Carl Thiem Klinikum Cottbus, Dept Internal Med 2, Cottbus, Germany
[13] Univ Hosp Koln, Dept Internal Med 1, Cologne, Germany
[14] Gemeinschaftsklinikum Mittelrhein, Dept Haematol & Oncol, Koblenz, Germany
关键词
myeloma; stem cell transplantation; single transplantation; tandem transplantation; melphalan; RANDOMIZED-TRIAL; INTERGROUPE FRANCOPHONE; MARROW-TRANSPLANTATION; 200 MG/M(2); THERAPY; MAINTENANCE; BORTEZOMIB; INDUCTION; LENALIDOMIDE; CHEMOTHERAPY;
D O I
10.1111/bjh.13994
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prospective, randomized phase III trial GMMG-HD2 aimed at demonstrating non-inferiority of single (Arm A) versus tandem (Arm B) high-dose melphalan followed by autologous transplantation (HDM/ASCT) with regard to 2-year event-free survival (EFS) in newly-diagnosed multiple myeloma (MM) and included 358 evaluable patients [Intention-to-treat population, (ITT), single/tandem HDM/ASCT: n=177/181]. After a median follow-up of more than 11years, non-inferiority of single versus tandem HDM/ASCT was demonstrated using the planned non-inferiority threshold of 15% of the 2-year EFS rate. Neither EFS (P=053) nor overall survival (OS) (P=033) differences were observed in the ITT population. In the tandem arm, 26% (n=47/181) of patients refused a second HDM/ASCT due to non-medical reasons. A per-protocol (PP) analysis, including patients who received the intervention (single/tandem HDM/ASCT: n=156/93) and patients who did not receive a second HDM/ASCT due to medical reasons (12%, n=22/181), did not yield differences in EFS (P=061) or OS (P=016). In the ITT and PP set of the tandem arm, the rates of complete responses increased from first to second HDM/ASCT (both P=004). Ten-year OS for the entire ITT was 34% (95% confidence interval: 29-40%). OS after first relapse was significantly shortened in the tandem arm (P=004). In this study single HDM/ASCT was non-inferior to tandem HDM/ASCT in MM.
引用
收藏
页码:731 / 741
页数:11
相关论文
共 37 条
[21]   How we manage autologous stem cell transplantation for patients with multiple myeloma [J].
Gertz, Morie A. ;
Dingli, David .
BLOOD, 2014, 124 (06) :882-890
[22]   Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis [J].
Kumar, Ambuj ;
Kharfan-Dabaja, Mohamed A. ;
Glasmacher, Axel ;
Djulbegovic, Benjamin .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (02) :100-106
[23]   Long-term prognostic significance of response in multiple myeloma after stem cell transplantation [J].
Martinez-Lopez, Joaquin ;
Blade, Joan ;
Mateos, Maria-Victoria ;
Grande, Carlos ;
Alegre, Adrian ;
Garcia-Larana, Jose ;
Sureda, Anna ;
de la Rubia, Javier ;
Conde, Eulogio ;
Martinez, Rafael ;
de Arriba, Felipe ;
Viguria, Maria C. ;
Besalduch, Joan ;
Cabrera, Rafael ;
Gonzalez-San Miguel, Jose D. ;
Luis Guzman-Zamudio, Jose ;
Carmen Gomez del Castillo, Ma ;
Ma Moraleda, Jose ;
Garcia-Ruiz, Juan C. ;
San Miguel, Jesus ;
Jose Lahuerta, Juan .
BLOOD, 2011, 118 (03) :529-534
[24]   Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma [J].
McCarthy, Philip L. ;
Owzar, Kouros ;
Hofmeister, Craig C. ;
Hurd, David D. ;
Hassoun, Hani ;
Richardson, Paul G. ;
Giralt, Sergio ;
Stadtmauer, Edward A. ;
Weisdorf, Daniel J. ;
Vij, Ravi ;
Moreb, Jan S. ;
Callander, Natalie Scott ;
Van Besien, Koen ;
Gentile, Teresa ;
Isola, Luis ;
Maziarz, Richard T. ;
Gabriel, Don A. ;
Bashey, Asad ;
Landau, Heather ;
Martin, Thomas ;
Qazilbash, Muzaffar H. ;
Levitan, Denise ;
McClune, Brian ;
Schlossman, Robert ;
Hars, Vera ;
Postiglione, John ;
Jiang, Chen ;
Bennett, Elizabeth ;
Barry, Susan ;
Bressler, Linda ;
Kelly, Michael ;
Seiler, Michele ;
Rosenbaum, Cara ;
Hari, Parameswaran ;
Pasquini, Marcelo C. ;
Horowitz, Mary M. ;
Shea, Thomas C. ;
Devine, Steven M. ;
Anderson, Kenneth C. ;
Linker, Charles .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (19) :1770-1781
[25]   Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma [J].
Moreau, P ;
Misbahi, R ;
Milpied, N ;
Morineau, N ;
Mahé, B ;
Vigier, M ;
Rapp, MJ ;
Bataille, R ;
Harousseau, JL .
LEUKEMIA, 2002, 16 (09) :1838-1843
[26]   Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial [J].
Moreau, P ;
Facon, T ;
Attal, M ;
Hulin, C ;
Michallet, M ;
Maloisel, F ;
Sotto, JJ ;
Guilhot, F ;
Marit, G ;
Doyen, C ;
Jaubert, A ;
Fuzibet, JG ;
François, S ;
Benboubker, L ;
Monconduit, M ;
Voillat, L ;
Macro, M ;
Berthou, C ;
Dorvaux, V ;
Pignon, B ;
Rio, B ;
Matthes, T ;
Casassus, P ;
Caillot, D ;
Najman, N ;
Grosbois, B ;
Bataille, R ;
Harousseau, JL .
BLOOD, 2002, 99 (03) :731-735
[27]   Benefit and timing of second transplantations in multiple myeloma: Clinical findings and methodological limitations in a European group for blood and marrow transplantation registry study [J].
Morris, C ;
Iacobelli, S ;
Brand, R ;
Bjorkstrand, B ;
Drake, M ;
Niederwieser, D ;
Gahrton, G .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1674-1681
[28]   First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies [J].
Naumann-Winter, Frauke ;
Greb, Alexander ;
Borchmann, Peter ;
Bohlius, Julia ;
Engert, Andreas ;
Schnell, Roland .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (10)
[29]   Autologous Transplantation and Maintenance Therapy in Multiple Myeloma [J].
Palumbo, A. ;
Cavallo, F. ;
Gay, F. ;
Di Raimondo, F. ;
Yehuda, D. B. ;
Petrucci, M. T. ;
Pezzatti, S. ;
Caravita, T. ;
Cerrato, C. ;
Ribakovsky, E. ;
Genuardi, M. ;
Cafro, A. ;
Marcatti, M. ;
Catalano, L. ;
Offidani, M. ;
Carella, A. M. ;
Zamagni, E. ;
Patriarca, F. ;
Musto, P. ;
Evangelista, A. ;
Ciccone, G. ;
Omede, P. ;
Crippa, C. ;
Corradini, P. ;
Nagler, A. ;
Boccadoro, M. ;
Cavo, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (10) :895-905
[30]   Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study [J].
Palumbo, Antonio ;
Bringhen, Sara ;
Bruno, Benedetto ;
Falcone, Antonietta Pia ;
Liberati, Anna Marina ;
Grasso, Mariella ;
Ria, Roberto ;
Pisani, Francesco ;
Cangialosi, Clotilde ;
Caravita, Tommaso ;
Levi, Anna ;
Meloni, Giovanna ;
Nozza, Andrea ;
Pregno, Patrizia ;
Gabbas, Attilio ;
Callea, Vincenzo ;
Rizzo, Manuela ;
Annino, Luciana ;
De Stefano, Valerio ;
Musto, Pellegrino ;
Baldi, Ileana ;
Cavallo, Federica ;
Petrucci, Maria Teresa ;
Massaia, Massimo ;
Boccadoro, Mario .
BLOOD, 2010, 115 (10) :1873-1879